Skip to Content

'
Nachman Mazurek, Ph.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Gastroenterology, Hepatology & Nutrition, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
7435 Fannin St
Unit Number: 955
Houston, TX 77030
Phone: 713-834-6140
Fax: 713-745-8279

Education & Training

Degree-Granting Education

1983 The Weizmann Institute of Science, The Feinberg Graduate School, Rehovot, Israel, PHD, Chemical Immunology
1978 Ben-Gurion University, Beer-Sheva, Israel, Israel, M.Sc, Physical Chemistry

Postgraduate Training

1/1994-2/1994 Phosphodiestrases, University of Washington, Seattle, WA
1/1985-1/1986 Research Fellowship, Postdoctoral Fellow, University Clinic Medical School, Basel, Switzerland, Dr. Eppenberger
1/1983-1/1985 Research Fellowship, Postdoctoral Fellow, Biozentrum (University of Basel), Basel, Switzerland, Dr. Schindler

Experience/Service

Academic Appointments

Associate Investigator, Gastroenterology, Division of Internal Medicine, Henry Ford Hospital, Detroit, MI, 1/1996-1/2002
Staff Scientist, Immunology, Otsuka America Pharmaceutical, Inc., Rockville, MD, 1/1994-1/1995
Assistant Professor, Department of Pathology, Head of Molecular Engineering, The Biomembrane Institute and University of Washington, Seattle, WA, 1/1990-1/1994
Scientist, Department of Membrane Research, Life Sciences, Weizmann Institute of Science, Rehovot, Israel, 1/1986-1/1990

Selected Publications

Peer-Reviewed Original Research Articles

1. Mazurek N, Byrd JC, Sun Y, Ueno S, Bresalier RS. A Galectin-3 Sequence Polymorphism Confers TRAIL Sensitivity to Human Breast Cancer Cells. Cancer 117(19):4375-80, 10/2011. e-Pub 3/2011. PMCID: PMC3164935.
2. Mazurek N, Byrd JC, Sun Y, Hafley M, Ramirez K, Burks J, Bresalier RS. Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. Cell Death Differ. e-Pub 9/2011. PMCID: PMC3246527.
3. Song S, Mazurek N, Liu C, Sun Y, Ding QQ, Liu K, Hung MC, Bresalier RS. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res 69(4):1343-9, 2/2009. e-Pub 2/2009. PMCID: PMC2990400.

Abstracts

1. Mazurek N, Byrd JC, Sun YJ, Bresalier RS. Nuclear galectin-3 confers tumor nucrosis factor-related apoptosis-inducing ligand (TRAIL) resistance to colon cancer cells by inhibiting caspase-8 activation. Gastroenterology 136(Suppl. 1):W1930, 2009.
2. Mazurek N, Sun Y, Liu KF, Bresalier RS. Galectin-3 loss leads to PTEN down-regulation and acquisiton of TRAIL-resistance in human colon cancer cells. Gastroenterology 130 (4), Suppl 2:A-668, 2006.

Grant & Contract Support

Title: Extracellular and Intracellular Forms of Galectin-3 in Colon Cancer Progression (Competitive Renewal of Mucin glycoproteins in colorectal cancer metastasis
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 7/1/2016 - 6/30/2017
 
Title: A Circulating Ligend for Galectin-3 in the Serum of Individuals with Colorectal Neoplasia: Population Differences in Caucatians and Hispanics in Puerto Rico and Houston
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Robert Bresalier
Duration: 10/1/2010 - 9/30/2011
 
Title: Early Detection Research Network, Great Lakes-New England Clinical, Epidemiology and Validation Center
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Robert Bresalier
Duration: 8/1/2010 - 7/31/2015
 
Title: A Circulating Ligand for Galectin-3 Elevated in the Serum of Individuals with Colorectal Neoplasia: prospective Evaluation Using a Newly Developed ELISA
Funding Source: G.S. Hogan Gastrointestinal Cancer Research Fund
Role: Co-Investigator
Duration: 8/1/2010 - 7/30/2011
 
Title: Mucin Glycoproteins in Colorectal Cancer Metastasis
Funding Source: NIH
Role: Co-Investigator
Principal Investigator: Bresalier, R
Duration: 9/2006 - 8/2012
 
Title: Early Detection Research Network, Great Lakes-New England Clinical and Epidemiology Center.
Funding Source: National Cancer Institute
Role: Co-Investigator
Principal Investigator: Dean Brenner
Duration: 3/1/2005 - 2/1/2010

Last updated: 3/14/2013